Study design The third and fourth premolars of 6 dogs were bilat

Study design. The third and fourth premolars of 6 dogs were bilaterally extracted with AMN-107 in vivo a full-thickness flap, and threaded implants presenting a textured or a polished surface at the cervical regions were placed on the distal root extraction sockets. Submerged healing was allowed for 4 weeks, and bone-to-implant contact (BIC) and buccal and lingual bone loss were morphometrically measured.

Results. The BIC and lingual bone loss were not significantly different between textured and polished groups. Significantly lower buccal bone loss (P < .01) was observed for the textured surface at 4 weeks in vivo.

Conclusion. Textured surface implants placed immediately

after tooth extraction resulted in less bone loss only at the buccal cervical region compared with smooth surface implants. (Oral Selleck CBL0137 Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110: 182-187)”
“Serum hepatitis B virus surface antigen (HBsAg) levels have been suggested to predict interferon response in chronic hepatitis B. A few data are available on the role of HBsAg measurement in nucleos(t)ide analogues (NA) treatment. We retrospectively investigated the relation between HBsAg changes and main treatment outcomes during long-term lamivudine treatment in hepatitis e antigen (HBeAg)negative chronic hepatitis B. A total of 42 HBeAg-negative patients were consecutively enrolled GS-7977 in vitro in an open-label study on long-term lamivudine

monotherapy (150 mg/die). Serum HBsAg levels were quantified every 6 months by Architect assay (Abbott Diagnostics). HBV-DNA was quantified quarterly by real-time PCR (Roche Diagnostics). The median duration of lamivudine treatment was 66 months (20-153). One patient (2%) was a primary nonresponder, 35 (83%) developed virological breakthrough (VB) and the remaining six patients (14%) were classified as long-term on-treatment responders. During treatment, HBsAg levels decreased only in long-term on-treatment responders, while no changes were observed

in resistant patients. Failure to achieve a decrease of 0.7 log(10) IU/mL in serum HBsAg at month six of lamivudine had a positive predictive value of developing VB of 90% and a negative predictive value of 100%. These high predictive values were also maintained in the subgroup of patients negative for HBV-DNA at month six. The results of this study with a small sample size suggest a role of on-treatment HBsAg quantification in the management of lamivudine-treated patients. If validated prospectively in a larger patient cohort, HBsAg measurements would be a useful adjunct to optimize antiviral therapy.”
“We have investigated the influence of the electric bias field on the magnetic and transport properties of (011)-oriented La0.9Ba0.1MnO3 (LBMO) thin film epitaxially grown on (011)-0.7Pb(Mg1/3Nb2/3)O-3-0.3PbTiO(3) (PMN-PT) single crystal substrate.

Comments are closed.